4//SEC Filing
ESPERION THERAPEUTICS INC/MI 4
Accession 0001209191-04-009423
CIK 0001066745operating
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 8:05 PM ET
Size
6.7 KB
Accession
0001209191-04-009423
Insider Transaction Report
Form 4
KRAUSE BRIAN R
VP Preclinical Res.& Discovery
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2004-02-10−129,179→ 0 total→ Common Stock (129,179 underlying)
Footnotes (2)
- [F1]These options, with exercise prices ranging from $4.19 - $6.75, and which provided for vesting in 16 equal quarterly installments at the end of each 3-month period from the date of grant, were canceled pursuant to the Agreement and Plan of Merger dated 12/19/03, as amended on 1/16/04, by and among Esperion, Enzo Aquisition Corp. and Pfizer Inc. Vested options were canceled in exchange for a cash payment representing the difference between the exercise prices of the options and the market value of the underlying common stock on the effective date of the merger ($35). With respect to the cash payment attributable to the unvested options, the Reporting Person will receive 50% of such cash payment immediately following the merger, and the remainder of such cash payment will be paid with interest on the third anniversary of the effective date of the merger, provided that the Reporting Person continues to be an employee of Esperion, Pfizer or any of their affiliates.
- [F2]The expiration dates of these options range from March 13, 2011 to February 6, 2013.
Documents
Issuer
ESPERION THERAPEUTICS INC/MI
CIK 0001066745
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001066745
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 8:05 PM ET
- Size
- 6.7 KB